Fused-Aromatic PPAR Gamma Agonists for Insulin Sensitivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type 2 diabetes, particularly PPAR agonists, face limitations such as liver toxicity, modest efficacy, and negative effects on lipid profiles, necessitating the development of more effective insulin sensitizers that address hyperglycemia and associated conditions like obesity and lipid disorders.
Innovation Solution
Development of a new class of PPAR-gamma agonists and partial agonists, which may also function as PPAR-alpha agonists, that act as potent ligands for the PPAR gamma nuclear receptor to treat hyperglycemia and insulin resistance, including conditions associated with type 2 diabetes like obesity and lipid disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PPAR agonists are used to treat type 2 diabetes, then insulin sensitivity is improved, but liver toxicity occurs
Solution Approach 1:
The patent modifies the chemical structure of PPAR agonists by changing molecular parameters such as introducing fused aromatic rings with specific functional groups (carboxylic acid, ester, amide, etc.) at defined positions. This structural parameter change aims to improve insulin sensitivity while reducing liver toxicity by optimizing the compound's interaction with PPAR receptors and its metabolic profile.
Solution Approach 2:
The invention creates composite molecular structures combining fused aromatic rings (naphthalene, anthracene, phenanthrene systems) with various functional groups and substituents. This composite approach allows tuning of pharmacological properties to achieve better therapeutic efficacy with reduced hepatotoxicity compared to simpler PPAR agonist structures.
2Reliability
If PPAR agonists are used to treat type 2 diabetes, then hyperglycemia is controlled, but efficacy is modest
Solution Approach 1:
The patent optimizes molecular parameters including the type of fused aromatic ring system, position and nature of substituents (halogens, alkyl groups, alkoxy groups), and functional group configuration to enhance PPAR receptor binding affinity and selectivity. These parameter changes are designed to improve therapeutic efficacy in controlling hyperglycemia beyond what conventional PPAR agonists achieve.
3Reliability
If PPAR agonists are used to treat type 2 diabetes, then insulin resistance is reduced, but lipid profile deteriorates
Solution Approach 1:
The patent introduces specific local structural features at defined positions of the fused aromatic core, such as placing carboxylic acid or ester groups at specific ring positions and adding particular substituents at selective locations. This local quality modification allows the compound to selectively improve insulin sensitivity in target tissues while having minimal adverse effects on lipid metabolism compared to other PPAR agonists.
Data Source
AI summary
Fused aromatic compounds of Formula (I) are PPAR gamma agonists or partial agonists and are useful in the treatment or control of type II diabetes, including hyperglycemia, dyslipidermia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.